Remove 2023 Remove Outcomes Remove Transplant
article thumbnail

CareDx Launches Two Expanded Indications for AlloSure Testing Services

DAIC

The Transplant Company recently announced that AlloSureis now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. 1 "The availability of AlloSure dd-cfDNA for all pediatric heart transplant patients is a major development.

article thumbnail

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

DAIC

In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ. utilizing the Paragonix SherpaPak CTS (p=0.022).

article thumbnail

Kidney Week 2023: Top Ten Takeaways

Cardiometabolic Health Congress

2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.

article thumbnail

The comparative impact of central vs. peripheral VA-ECMO cannulation on postoperative graft dysfunction in lung transplantation: a retrospective analysis

Frontiers in Cardiovascular Medicine

BackgroundLung transplantation (LTx) is the definitive treatment for end-stage pulmonary diseases, with venoarterial extracorporeal membrane oxygenation (VA-ECMO) used as a common perioperative support. Data included recipient/donor demographics, preoperative status, and follow-up outcomes.

article thumbnail

Abstract 4146920: Potential Effects of Preoperative Blood Transfusions on Cardiac Transplantation Patient’s Postoperative Condition

Circulation

Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While

article thumbnail

Trends in Ductus Arteriosus Stent Versus Blalock?Taussig?Thomas Shunt Use and Comparison of Cost, Length of Stay, and Short?Term Outcomes in Neonates With Ductal?Dependent Pulmonary Blood Flow: An Observational Study Using the Pediatric Health Information Systems Database

Journal of the American Heart Association

Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. Intervention was not significantly associated with odds of 30‐day transplant‐free survival (OR,1.18 [95% CI, 0.70–1.99]) 1.58]), but DAS was associated with 30‐day freedom from composite adverse outcome (OR, 1.51 [95% CI, 1.11–2.05]).ConclusionsUse

article thumbnail

Transcatheter Palliation With Pulmonary Artery Flow Restrictors in Neonates With Congenital Heart Disease: Feasibility, Outcomes, and Comparison With a Historical Hybrid Stage 1 Cohort

Circulation: Cardiovascular Interventions

Data on transcatheter palliation are limited.Methods:We present our experience with pulmonary flow restrictors (PFRs) for palliation of neonates with congenital heart disease, including procedural feasibility, technical details, and outcomes. kilograms [IQR, 2.1–3.3])